Bone morphogenetic protein 7: A broad-spectrum growth factor with multiple target therapeutic potency

Cytokine and Growth Factor Reviews

Volumn 22, Issue 4, 2011, Pages 221-229

  Boon, Mariëtte R ^a   van der Horst, Geertje ^a   van der Pluijm, Gabri ^a   Tamsma, Jouke T ^a   Smit, Johannes W A ^a   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BMP7; Bone metastasis; Brown adipose tissue; Kidney fibrosis; Obesity

Indexed keywords

2,4 DINITROPHENOL; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; COLLAGEN; EPHEDRINE; FENFLURAMINE; FLUORODEOXYGLUCOSE F 18; GROWTH FACTOR; OSTEOGENIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RECOMBINANT OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

BONE DEVELOPMENT; BONE METASTASIS; BROWN ADIPOSE TISSUE; CATARACT; DIABETES MELLITUS; DRUG POTENCY; DRUG TARGETING; DRUG WITHDRAWAL; FRACTURE NONUNION; HUMAN; HYPERTHERMIA; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; KNEE OSTEOARTHRITIS; NONHUMAN; OBESITY; OSTEOARTHRITIS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE DIFFERENTIATION; UNSPECIFIED SIDE EFFECT;

ADIPOSE TISSUE, BROWN; ANIMALS; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEIN 7; BONE NEOPLASMS; BONE REGENERATION; CELL DIFFERENTIATION; FIBROSIS; FRACTURES, BONE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY DISEASES; NEOPLASM METASTASIS; OBESITY; OSTEOARTHRITIS;

EID: 81155149867     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.08.001     Document Type: Review

References (97)

1. Gazzerro E., Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006, 7:51-65.
2. Kawabata M., Imamura T., Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998, 9:49-61.
3. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
4. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009, 20:343-355.
5. Bragdon B., Moseychuk O., Saldanha S., King D., Julian J., Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal 2010.
6. Scheufler C., Sebald W., Hulsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol 1999, 287:103-115.
7. Miyazono K., Kusanagi K., Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 2001, 187:265-276.
8. Buijs J.T., Henriquez N.V., van Overveld P.G., van der Horst G., Que I., Schwaninger R., et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007, 67:8742-8751.
9. Wang S.N., Lapage J., Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001, 12:2392-2399.
10. Luyten F.P., Cunningham N.S., Ma S., Muthukumaran N., Hammonds R.G., Nevins W.B., et al. partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 1989, 264:13377-13380.
11. Sampath T.K., Muthukumaran N., Reddi A.H. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci U S A 1987, 84:7109-7113.
12. Wang E.A., Rosen V., Cordes P., Hewick R.M., Kriz M.J., Luxenberg D.P., et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988, 85:9484-9488.
13. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
14. Sampath T.K., Maliakal J.C., Hauschka P.V., Jones W.K., Sasak H., Tucker R.F., et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992, 267:20352-20362.
15. Vukicevic S., Luyten F.P., Reddi A.H. Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci U S A 1989, 86:8793-8797.
16. Reddi A.H. Initiation of fracture repair by bone morphogenetic proteins. Clin Orthop Relat Res 1998, S66-S72.
17. Einhorn T.A. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998, S7-S21.
18. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007, 77:626-631.
19. Rodriguez-Merchan E.C., Forriol F. Nonunion: general principles and experimental data. Clin Orthop Relat Res 2004, 4-12.
20. Cook S.D., Baffes G.C., Wolfe M.W., Sampath T.K., Rueger D.C. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop Relat Res 1994, 30:2-312.
21. Cook S.D., Baffes G.C., Wolfe M.W., Sampath T.K., Rueger D.C., Whitecloud T.S. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am 1994, 76:827-838.
22. Cook S.D., Wolfe M.W., Salkeld S.L., Rueger D.C. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 1995, 77:734-750.
23. Friedlaender G.E., Perry C.R., Cole J.D., Cook S.D., Cierny G., Muschler G.F., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001, 83-A(Suppl 1:):S151-S158.
24. Moghaddam A., Elleser C., Biglari B., Wentzensen A., Zimmermann G. Clinical application of BMP 7 in long bone non-unions. Arch Orthop Trauma Surg 2010, 130:71-76.
25. Wozney J.M., Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998, 2:6-37.
26. Harwood P.J., Giannoudis P.V. Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects. Expert Opin Drug Saf 2005, 4:75-89.
27. Prevalence of disabilities and associated health conditions among adults - United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50:120-5.
28. Glazier R.H., Dalby D.M., Badley E.M., Hawker G.A., Bell M.J., Buchbinder R., et al. Management of common musculoskeletal problems: a survey of Ontario primary care physicians. CMAJ 1998, 158:1037-1040.
29. Lories R.J., Luyten F.P. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011, 7:43-49.
30. Fan Z., Chubinskaya S., Rueger D.C., Bau B., Haag J., Aigner T. Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. Clin Exp Rheumatol 2004, 22:103-106.
31. Flechtenmacher J., Huch K., Thonar E.J., Mollenhauer J.A., Davies S.R., Schmid T.M., et al. Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996, 39:1896-1904.
32. Nishida Y., Knudson C.B., Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage 2004, 12:374-382.
33. Huch K., Wilbrink B., Flechtenmacher J., Koepp H.E., Aydelotte M.B., Sampath T.K., et al. Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum 1997, 40:2157-2161.
34. Koepp H.E., Sampath K.T., Kuettner K.E., Homandberg G.A. Osteogenic protein-1 (OP-1) blocks cartilage damage caused by fibronectin fragments and promotes repair by enhancing proteoglycan synthesis. Inflamm Res 1999, 48:199-204.
35. Im H.J., Pacione C., Chubinskaya S., Van Wijnen A.J., Sun Y., Loeser R.F. Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem 2003, 278:25386-25394.
36. Chen P., Vukicevic S., Sampath T.K., Luyten F.P. Bovine articular chondrocytes do not undergo hypertrophy when cultured in the presence of serum and osteogenic protein-1. Biochem Biophys Res Commun 1993, 197:1253-1259.
37. Chen P., Vukicevic S., Sampath T.K., Luyten F.P. Osteogenic protein-1 promotes growth and maturation of chick sternal chondrocytes in serum-free cultures. J Cell Sci 1995, 108(Pt 1):105-114.
38. Vukicevic S., Latin V., Chen P., Batorsky R., Reddi A.H., Sampath T.K. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high affinity binding to basement membranes. Biochem Biophys Res Commun 1994, 198:693-700.
39. Chubinskaya S., Merrihew C., Cs-Szabo G., Mollenhauer J., McCartney J., Rueger D.C., et al. Human articular chondrocytes express osteogenic protein-1. J Histochem Cytochem 2000, 48:239-250.
40. Chubinskaya S., Kumar B., Merrihew C., Heretis K., Rueger D.C., Kuettner K.E. Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1). Biochim Biophys Acta 2002, 1588:126-134.
41. Merrihew C., Kumar B., Heretis K., Rueger D.C., Kuettner K.E., Chubinskaya S. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. J Orthop Res 2003, 21:899-907.
42. Soder S., Hakimiyan A., Rueger D.C., Kuettner K.E., Aigner T., Chubinskaya S. Antisense inhibition of osteogenic protein 1 disturbs human articular cartilage integrity. Arthritis Rheum 2005, 52:468-478.
43. Grgic M., Jelic M., Basic V., Basic N., Pecina M., Vukicevic S. Regeneration of articular cartilage defects in rabbits by osteogenic protein-1 (bone morphogenetic protein-7). Acta Med Croatica 1997, 51:23-27.
44. Mason J.M., Breitbart A.S., Barcia M., Porti D., Pergolizzi R.G., Grande D.A. Cartilage and bone regeneration using gene-enhanced tissue engineering. Clin Orthop Relat Res 2000, S171-S178.
45. Cook S.D., Patron L.P., Salkeld S.L., Rueger D.C. Repair of articular cartilage defects with osteogenic protein-1 (BMP-7) in dogs. J Bone Joint Surg Am 2003, 85-A(Suppl. 3):116-123.
46. Jelic M., Pecina M., Haspl M., Kos J., Taylor K., Maticic D., et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 2001, 19:101-113.
47. Louwerse R.T., Heyligers I.C., Klein-Nulend J., Sugihara S., van Kampen G.P., Semeins C.M., et al. Use of recombinant human osteogenic protein-1 for the repair of subchondral defects in articular cartilage in goats. J Biomed Mater Res 2000, 49:506-516.
48. Hunter D.J., Pike M.C., Jonas B.L., Kissin E., Krop J., McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010, 11:232.
49. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
50. Tang B., Vu M., Booker T., Santner S.J., Miller F.R., Anver M.R., et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112:1116-1124.
51. Buijs J.T., Rentsch C.A., van der Horst G., van Overveld P.G., Wetterwald A., Schwaninger R., et al. BMP7 a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007, 171:1047-1057.
52. Harris S.E., Harris M.A., Mahy P., Wozney J., Feng J.Q., Mundy G.R. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994, 24:204-211.
53. Dolan V., Hensey C., Brady H.R. Diabetic nephropathy: renal development gone awry?. Pediatr Nephrol 2003, 18:75-84.
54. Vukicevic S., Kopp J.B., Luyten F.P., Sampath T.K. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci U S A 1996, 93:9021-9026.
55. Dudley A.T., Lyons K.M., Robertson E.J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 1995, 9:2795-2807.
56. Gould S.E., Day M., Jones S.S., Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002, 61:51-60.
57. http://www.usrds.org/.
58. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004, 85:47-64.
59. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003.
60. Ledbetter S., Kurtzberg L., Doyle S., Pratt B.M. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000, 58:2367-2376.
61. Ziyadeh F.N., Hoffman B.B., Han D.C. Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
62. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49:461-469.
63. Marti H.P., Lee L., Kashgarian M., Lovett D.H. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994, 144:82-94.
64. Martin J., Steadman R., Knowlden J., Williams J., Davies M. Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro. J Am Soc Nephrol 1998, 9:1629-1637.
65. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
66. Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995, 154:8-20.
67. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
68. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
69. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21:212-222.
70. Grgic I., Duffield J.S., Humphreys B.D. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2011.
71. Biyikli N.K., Tugtepe H., Cakalagaoglu F., Ilki A., Alpay H. Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis. Pediatr Nephrol 2005, 20:1230-1236.
72. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814-1818.
73. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968.
74. Patel S.R., Dressler G.R. BMP7 signaling in renal development and disease. Trends Mol Med 2005, 11:512-518.
75. Wang S., Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004, 279:23200-23206.
76. Vukicevic S., Basic V., Rogic D., Basic N., Shih M.S., Shepard A., et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998, 102:202-214.
77. Wang S., Chen Q., Simon T.C., Strebeck F., Chaudhary L., Morrissey J., et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003, 63:2037-2049.
78. Li T., Surendran K., Zawaideh M.A., Mathew S., Hruska K.A. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 2004, 13:417-422.
79. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004, 84:277-359.
80. Enerback S. Human brown adipose tissue. Cell Metab 2010, 11:248-252.
81. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A.B., et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009, 360:1509-1517.
82. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D., et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009, 360:1500-1508.
83. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T., et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009, 360:1518-1525.
84. Fruhbeck G., Becerril S., Sainz N., Garrastachu P., Garcia-Velloso M.J. BAT: a new target for human obesity?. Trends Pharmacol Sci 2009, 30:387-396.
85. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454:961-967.
86. Timmons J.A., Wennmalm K., Larsson O., Walden T.B., Lassmann T., Petrovic N., et al. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. Proc Natl Acad Sci U S A 2007, 104:4401-4406.
87. Petrovic N., Walden T.B., Shabalina I.G., Timmons J.A., Cannon B., Nedergaard J. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem 2010, 285:7153-7164.
88. Schulz T.J., Huang T.L., Tran T.T., Zhang H., Townsend K.L., Shadrach J.L., et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc Natl Acad Sci U S A 2011, 108:143-148.
89. Tseng Y.H., Kokkotou E., Schulz T.J., Huang T.L., Winnay J.N., Taniguchi C.M., et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008, 454:1000-1004.
90. Vijgen G.H., Bouvy N.D., Teule G.J., Brans B., van Schrauwen P., Marken Lichtenbelt W.D. Brown adipose tissue in morbidly obese subjects. PLoS One 2011, 6:e17247.
91. Dulloo A.G., Miller D.S. Energy balance following sympathetic denervation of brown adipose tissue. Can J Physiol Pharmacol 1984, 62:235-240.
92. Tainter M.L., Cutting W.C., Stockton A.B. Use of dinitrophenol in nutritional disorders: a critical survey of clinical results. Am J Public Health Nations Health 1934, 24:1045-1053.
93. Harper J.A., Dickinson K., Brand M.D. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2001, 2:255-265.
94. Baba S., Tatsumi M., Ishimori T., Lilien D.L., Engles J.M., Wahl R.L. Effect of nicotine and ephedrine on the accumulation of 18F-FDG in brown adipose tissue. J Nucl Med 2007, 48:981-986.
95. Levitsky D.A., Troiano R. Metabolic consequences of fenfluramine for the control of body weight. Am J Clin Nutr 1992, 55:167S-172S.
96. Lupien J.R., Bray G.A. Effect of fenfluramine on GDP-binding to brown adipose tissue mitochondria. Pharmacol Biochem Behav 1985, 23:509-511.
97. Subramanian S., Vollmer R.R. Sympathetic activation by fenfluramine depletes brown adipose tissue norepinephrine content in rats. Pharmacol Biochem Behav 2002, 73:639-645.